Inve India ▾
TATARSONS

Tarsons Products Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 25 May 2026

Tarsons Products reported a resilient Q4 and FY26, with consolidated revenue growing 7.3% and 7.7% YoY respectively, driven by strong domestic performance. However, export business faced headwinds due to geopolitical tensions, leading to a 13.4% decline in Q4. Margins were pressured by rising raw material costs and higher depreciation from new capex, though Adjusted Cash PAT saw robust 21.4% YoY growth. The company anticipates full commissioning of its capex program in H1 FY27, expecting initial benefits from higher volumes and improved product availability.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q4 FY26: revenue up 7.3%, net profit down 59.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue99 96 113 91 102 +3%108 +13%121 +7%
EBITDA25 30 37 25 27 +8%32 +6%34 −7%
Net profit10 5 10 2 3 −68%5 −4%4 −59%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.